Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Proper maintenance of plasma membrane (PM) cholesterol is essential for diverse processes ranging from animal development to pathogen evasion. Despite decades of study, the mechanisms governing cellular cholesterol regulation are incomplete. Using genome-wide screens we find that ACC1, the rate-limiting enzyme in fatty acid biosynthesis, regulates PM cholesterol transport. ACC1 loss causes a ∼10-fold increase in PM accessible cholesterol in cells and mice. Mechanistically, we find that ACC1 regulates lipid droplet (LD) catabolism, and LDs are intimately tied to PM accessible cholesterol levels since reductions or elevations in their numbers block or promote cholesterol trafficking, respectively. Furthermore, LDs are required for cholesterol trafficking induced by 25-hydroxycholesterol, a modulator of inflammation and an interferon-stimulated second messenger that protects cells from pathogen invasion. This work identifies an unrecognized role for ACC1 and LDs in cholesterol regulation, which has implications for diseases where LD numbers are altered, from metabolic syndromes to neurodegeneration.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12407704 | PMC |
| http://dx.doi.org/10.1101/2025.08.21.671640 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Proper maintenance of plasma membrane (PM) cholesterol is essential for diverse processes ranging from animal development to pathogen evasion. Despite decades of study, the mechanisms governing cellular cholesterol regulation are incomplete. Using genome-wide screens we find that ACC1, the rate-limiting enzyme in fatty acid biosynthesis, regulates PM cholesterol transport.
View Article and Find Full Text PDFUnveiling the Metabolic Burden: A Clinicopathological Study of Chronic Plaque Psoriasis and Its Association With Metabolic Syndrome.
Cureus
August 2025
Department of Pathology, Mahatma Gandhi Memorial Medical College, Indore, IND.
Introduction Psoriasis is a chronic, immune-mediated inflammatory skin disease with systemic manifestations. Among its significant comorbidities, metabolic syndrome (MS) - a constellation of obesity, hypertension, dyslipidemia, and insulin resistance - has gained recognition due to its association with increased cardiovascular risk and reduced life expectancy. Chronic systemic inflammation, shared immunological pathways, and elevated pro-inflammatory cytokines are thought to underlie this association.
View Article and Find Full Text PDFComparison of Artificial Intelligence Models and Human Experts in Managing Dyslipidemia: Assessment of Adherence to Clinical Guidelines.
Cureus
August 2025
Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, TUR.
Objective The objective of this study is to compare guideline adherence between artificial intelligence (AI) models (Claude-3 (Anthropic, San Francisco, CA), DeepSeek-V2 (DeepSeek, Hangzhou, China), GPT-4 (OpenAI, San Francisco, CA)) and human experts in dyslipidemia management using standardized clinical scenarios based on 2019 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) and 2021 ESC prevention guidelines. The study employed a comprehensive evaluation framework to capture the holistic nature of dyslipidemia management across multiple interconnected domains. Methods Thirty fictitious but clinically representative cases were developed by lipid specialists across five domains: cardiovascular risk assessment, lipid management, lifestyle modifications, pharmacotherapy, and special populations.
View Article and Find Full Text PDFChoosing the optimal nonstatin lipid lowering therapies for statin-intolerant patients: A systematic review and network meta-analysis.
J Clin Lipidol
August 2025
The Research Unit of Evidence Synthesis (TRUES), Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand (Dr. Dhippayom); Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT, USA (Dr. Dhippayom).
Background: Statin intolerance presents a considerable challenge in managing patients at risk for cardiovascular diseases, as it limits patients' access to standard lipid-lowering therapies.
Objective: This study aims to compare the efficacy and safety of various nonstatin lipid-lowering therapies in patients who are intolerant to statins.
Methods: We searched PubMed, Embase, CENTRAL, and EBSCO open dissertations through September 2023 for randomized controlled trials in statin-intolerant patients comparing nonstatin lipid-lowering agents.
The multi-dimensional regulatory mechanism of Sirt6 in heart health: From cell death pathways to targeted therapy for cardiovascular diseases.
Biochem Biophys Res Commun
August 2025
Institute of Cardiovascular Diseases, Hubei Province Key Laboratory of Occupational Hazard Identification and Control, School of Medicine, Wuhan University of Science and Technology, Wuhan, China; Wuhan Asia Heart Hospital, Wuhan University of Science and Technology, Wuhan, Hubei, China. Electronic
Sirtuin 6 (Sirt6) is a member of the Sirtuin family, exhibiting histone deacetylase and ADP-ribosyltransferase activity. This enzyme is involved in several pathways, such as epigenetic regulation and inflammation control. It is essential for preserving cardiac equilibrium and postponing the emergence of cardiovascular disorders.
View Article and Find Full Text PDF